Search

Your search keyword '"Vigano M."' showing total 84 results

Search Constraints

Start Over You searched for: Author "Vigano M." Remove constraint Author: "Vigano M." Publisher elsevier ltd Remove constraint Publisher: elsevier ltd
84 results on '"Vigano M."'

Search Results

1. Head Down Tilt 15° in Acute Ischemic Stroke with Poor Collaterals: A Randomized Preclinical Trial

2. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

3. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

7. Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid

15. Impact of HBV infection in HCV/HBV coinfected patients treated with DAAs IN Northern Italy

16. Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients

18. Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy

24. Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics

27. Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: A multicenter real-life study in 103 patients

40. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis

42. T-12 Tenofovir suppressed viral suppression in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European study

43. T-11 5-year entecavir in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC

45. P.15.2 ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT

47. OC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE

48. T-8 Entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B from field practice: high efficacy and favorable safety profile over 3 years of treatment

50. T-9 2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice

Catalog

Books, media, physical & digital resources